NCT04547894View on ClinicalTrials.gov

A Study of the Pharmacokinetics of ASC09F in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 9, 2020

Primary Completion Date

December 7, 2020

Study Completion Date

December 7, 2020

Conditions
Healthy
Interventions
DRUG

ASC09F

ASC09F (300 mg ASC09 and 100 mg Ritonavir) one tablet at a time, once per day, up to 7 days.

Trial Locations (1)

100069

Beijing Youan Hospital, Capital Medical University, Beijing

Sponsors
All Listed Sponsors
collaborator

Beijing YouAn Hospital

OTHER

lead

Ascletis Pharmaceuticals Co., Ltd.

INDUSTRY

NCT04547894 - A Study of the Pharmacokinetics of ASC09F in Healthy Subjects | Biotech Hunter | Biotech Hunter